Exemestane Tablets

What Is Exemestane and How It Differs from Other Aromatase Inhibitors

Exemestane (Aromasin) is a steroidal aromatase inactivator — the only AI in widespread use among athletes that permanently deactivates aromatase enzymes rather than temporarily blocking them. While Anastrozole Tablets and Letrozole are non-steroidal compounds that compete with androgens for the aromatase active site (reversible inhibition), Exemestane binds irreversibly to aromatase and destroys the enzyme's function entirely.

This single mechanistic difference has practical consequences that make Exemestane the preferred AI in specific situations — particularly at cycle end, during PCT transition, and for athletes who have experienced estrogen rebound when stopping other AIs.

Why Irreversible Inhibition Matters

When a reversible AI like Anastrozole is discontinued, aromatase enzyme activity returns — and if estrogen has been suppressed for weeks, the rebound can overshoot baseline. Elevated estrogen post-cycle compounds the hormonal disorder that PCT is trying to correct.

Exemestane destroys the aromatase enzyme itself. When you stop taking it, new aromatase must be synthesized from scratch. Estrogen levels rise gradually as new enzyme is produced — not sharply, not with overshoot. This eliminates the rebound effect entirely and makes the transition from on-cycle AI use to PCT significantly cleaner.

The Steroidal Structure: An Additional Advantage

Because Exemestane is derived from androstenedione — an androgenic precursor — its metabolite (17-hydroexemestane) has weak but measurable androgenic activity. In practice this means:

• Mild androgenic contribution during the cycle without additional compounds
• Less severe impact on bone density than non-steroidal AIs, which carry a significant long-term bone mineral loss risk at sustained use
• Less negative effect on the lipid profile compared to Anastrozole at equivalent estrogen suppression levels
• No interference with IGF-1 — some research suggests non-steroidal AIs may reduce IGF-1, which is not observed with Exemestane

Dosage and Protocol

Exemestane is highly potent. Most athletes use significantly less than the clinical dose used in breast cancer treatment:

• Conservative on-cycle use: 12.5 mg every other day — suits moderate aromatizing cycles (single testosterone ester at standard doses)
• Standard on-cycle use: 25 mg every other day — suits heavier cycles with multiple aromatizing compounds
• High-aromatization cycles (e.g., Andropen 450 or Sustabol 350 at high doses with oral Methanabol Tablets): 25 mg daily in the first weeks, reducing once blood levels stabilize
• PCT transition protocol: continue Exemestane at 12.5–25 mg every other day during the wait period before starting SERMs, then taper off as PCT begins
• Take with food — Exemestane absorption increases significantly with a fatty meal

Exemestane vs Anastrozole: When to Choose Which

Both compounds effectively control estrogen on cycle. The decision comes down to cycle structure and phase:

• For mid-cycle estrogen control on standard cycles: Anastrozole Tablets allow fine-tuned, reversible adjustment. If estrogen drops too low, stopping Anastrozole allows levels to recover within days
• For high-aromatization cycles or athletes prone to gynecomastia: Exemestane's irreversible action provides more aggressive and stable suppression
• For the final weeks of a cycle and PCT transition: Exemestane is the better choice — no rebound means estrogen remains controlled as the cycle ends and the SERM phase begins
• For athletes who have experienced estrogen rebound after previous cycles: switching to Exemestane for the cycle's final 4 weeks eliminates this risk

For a detailed side-by-side comparison see: Arimidex vs Aromasin on Cycle.

Using Exemestane During PCT

An important nuance: Exemestane can be run alongside SERMs during PCT where Anastrozole cannot comfortably be used at full dose. When combined with Tamoxifen Tablets or Clomiphene Tablets, Exemestane at 12.5 mg every other day controls any residual estrogen without suppressing it so aggressively that recovery is impaired.

The rule for AI use during PCT applies to all AIs: avoid over-suppressing estrogen during hormonal recovery. Estrogen plays a role in the HPG axis recovery process. Use the minimum Exemestane dose necessary and taper off as natural testosterone rises.

Side Effects of Exemestane

Exemestane's side effects are class effects of estrogen suppression — shared with all AIs, but generally milder than those of non-steroidal AIs at equivalent estrogen reduction:

• Joint pain, stiffness, and dryness — estrogen plays a lubricating role in connective tissue. Aggressive suppression at high doses causes joint discomfort. Reducing the dose resolves this.
• Bone mineral density reduction — a risk with sustained high-dose AI use. Exemestane's mild androgenic activity partially offsets this compared to Anastrozole or Letrozole.
• Fatigue and low mood — estrogen deficiency affects energy and mood in both men and women. Symptoms indicate over-suppression — dose should be reduced.
• Cholesterol alteration — less pronounced with Exemestane than with non-steroidal AIs, but still present at consistent high doses. Relevant on long cycles.

Conclusion

Exemestane Tablets by British Dragon occupy a specific and important role that no other AI can fill: irreversible estrogen suppression without rebound. For athletes transitioning off cycle, managing the final weeks of a heavy aromatizing protocol, or structuring a clean PCT, the absence of estrogen rebound is not a minor detail — it directly affects how smoothly hormonal recovery proceeds.

Used at sensible doses and timed correctly within the cycle, Exemestane is one of the most practically valuable support compounds in the British Dragon lineup — not for what it builds, but for what it protects.